ArticleDrug delivery2021
Novel cubosome based system for ocular delivery of acetazolamide.
Article in Drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Advanced Ophthalmic Drug Delivery in Homocystinuria Type CblC: A Translational Review of Ophthalmic Pathologies and Therapeutic Opportunities.Pharmaceutics · 2026Review
- Sustained Ocular Delivery of Moxifloxacin-Ufasomes-Laden In Situ Gel for Keratitis Management.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Recent Advances in Artificial Intelligence and Nanotechnology-Driven Strategies for Diagnosis and Therapy of Ocular Diseases.Current drug delivery · 2026Review
- Detailed Comprehensive Review on Advancement of Cubosomes and their Currently Available Applications.Current pharmaceutical biotechnology · 2026Review
- Oleic acid Enriched Leciplexes as Novel Mucoadhesive Cationic Nanocarriers of Agomelatine for Glaucoma Treatment.AAPS PharmSciTech · 2025Article
- An Insight into Cubosomal Drug Delivery Approaches: An Explicative Review.Pharmaceutical nanotechnology · 2025Review
- Untangling Breast Cancer: Trailing Towards Nanoformulations-based Drug Development.Recent patents on nanotechnology · 2025Review
- Recent Advances in Ocular Drug Delivery: Insights into Lyotropic Liquid Crystals.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Development of antifungal fibrous ocular insert using freeze-drying technique.Drug delivery and translational research · 2024Article
- Microporation-Mediated Transdermal Delivery of In Situ Gel Incorporating Etodolac-Loaded PLGA Nanoparticles for Management of Rheumatoid Arthritis.Pharmaceutics · 2024Article
- Cubosomal nanoformulation increaseTherapeutic delivery · 2024Article
- Vesicular Drug Delivery Systems: Promising Approaches in Ocular Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Ophthalmic Bimatoprost-Loaded Niosomal In Situ Gel: Preparation, Optimization, and In Vivo Pharmacodynamics Study.Polymers · 2023Article
- Development of Osthole-Loaded Microemulsions as a Prospective Ocular Delivery System for the Treatment of Corneal Neovascularization: In Vitro and In Vivo Assessments.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies.Journal of clinical medicine · 2023Review
- Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases.Pharmaceutics · 2023Review
- Cubosomes in Drug Delivery-A Comprehensive Review on Its Structural Components, Preparation Techniques and Therapeutic Applications.Biomedicines · 2023Review
- Breaking Barriers in Eye Treatment: Polymeric Nano-Based Drug-Delivery System for Anterior Segment Diseases and Glaucoma.Polymers · 2023Review
- Preparation and Evaluation of Modified Chitosan Nanoparticles Using Anionic Sodium Alginate Polymer for Treatment of Ocular Disease.Pharmaceutics · 2022Article
- A Versatile Nanocarrier-Cubosomes, Characterization, and Applications.Nanomaterials (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acetazolamide is the drug of choice for glaucoma treatment in an emergency. However, it is not available in any topical formulation and it is available only as systemic tablets. Despite its efficiency as a drug in decreasing intraocular pressure, it has negative systemic effects as renal toxicity and metabolic acidosis. Moreover, it suffers from poor aqueous solubility and low corneal permeability limiting its ocular bioavailability and its use topically. Cubosomes have enormous advantages as a drug delivery system, most importantly, high surface area, thermal stability, and ability to encapsulate hydrophobic, amhiphilic, and hydrophilic molecules. Herein, we have exploited the unique properties of cubosomes as a novel nano-delivery system for acetazolamide as eye drops dosage form for glaucoma treatment. Different acetazolamide-loaded cubosomes have been developed and evaluated. The best-optimized formulation (F5), was cubic shaped structure, with an average particle size of 359.5 ± 2.8 nm, surface charge -10.8 ± 3.2 mV, and 59.8% entrapment efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.